PBT which was flat, uninspiring outlook (trading -15.5%) Carpetright prelims, tough year, PBT down, no dividend, net debt reduced (trading +5.4%) Stagecoach FY pretax beats, ups div 10%, positive outlook, revs inline, good start to year (trading +5.6%) Grifols competitor Baxter gets FDA approval for Gammag